NY-DELOS
11.5.2020 15:17:07 CEST | Business Wire | Press release
In response to the coronavirus pandemic, Delos, a wellness real estate and technology company, has formed a collaboration with Humanity 2.0 Well Being and the Pontifical Orientale Institute to upgrade the Vatican’s Orientale’s residences with its evidence-based health and wellness technologies and solutions.
Rome and the Vatican are slowly emerging from lockdown, providing a critical window to help build health resilience, prevent disease and reduce viral transmission in houses, offices, parishes and school facilities through scientifically-supported technologies and solutions.
Delos, the trusted scientific authority on healthy buildings, has customized a program for the Pontifical Orientale Institute, which includes air purification and surface cleaning technology, circadian lighting and other evidence-based interventions designed to help support immune health, reduce stress, improve sleep quality and promote overall well-being.
In partnership with Humanity 2.0 Well Being, the wellness platform created in collaboration with the Vatican (Holy See), the Pontifical Orientale Institute was identified due to its rich history and innovative leadership, as well as vital role in convening global interfaith groups at the Vatican. Led by Rev. David Nazar, S.J, the Pontifical Oriental Institute was created by Pope Benedict XV in 1917, and is currently a school of higher studies that has as its particular mission the service of the Oriental Churches.
“The Catholic Church runs the largest governmental school system in the world, serving in over 100 countries - some over 1,000 years old - and runs one-quarter of the world's health care institutions,” said Father David Nazar, Rector of the Orientale. “Its preoccupation has always been the care of the entire person and of society. Recent information technology and wellness sciences have brought to the fore much needed insights into humanizing the educational environment. Our students come from over 40 countries, many without deep resources, and student depression is an increasing phenomenon in a world that is struggling to find a common purpose. COVID-19 has shown us how fragile we are. With Delos and Humanity 2.0 Well Being, we will be implementing health and wellness tools that address these contemporary educational challenges, helping us continue our focus on strengthening the whole person- body, mind, and spirit. Pope Francis, with his focus on human ecology, has asked church institutions to show leadership. With Delos and Humanity 2.0 Well Being, the Orientale is doing just that.”
“We are honored to have been asked to customize our suite of research and technology solutions accrued over years into a first-of-its-kind program for the Pontifical Orientale Institute residences at this pivotal time,” said Paul Scialla, Founder and CEO of Delos. “We know that buildings have a profound impact on human health, but the current pandemic has magnified the essential need for evidence-based health interventions in the indoor environment, which are being shared with the Vatican and its global network.”
Given the Catholic Church’s global footprint, comprising 200,000 colleges, universities and other schools, 220,000 parishes, 117,000 nursing home and senior living facilities, and 10,000 orphanages in 196 countries, Delos’ Vatican program at the Orientale will be made available more widely to the Catholic Church to educate and shape institutional best practices.
“Through upgrading our educational buildings with health innovations, we are actually building human capacity at one of its most formative periods,” said Morad Fareed, CEO of Humanity 2.0 Well Being and a co-founder of Delos. “Father Nazar and the Orientale have a heritage as pioneers, and this initial partnership is both a template and a catalyst for greater strategic collaboration with the Vatican at this defining time.”
With the support of Pope Francis, and in conjunction with Fr. William Watson, S.J., vice president for advancement for the Orientale, the Orientale’s residences, offices, classrooms and library/conference facilities were significantly upgraded in 2017- the 100th anniversary of the Institute. These same residences will now become the first residences in the Vatican to implement Delos’ technologies and solutions.
The collaboration with Delos and Humanity 2.0 Well Being is advanced by the Orientale’s initiative to upgrade the technology infrastructure for all Orientale classrooms to enable the most comprehensive distance learning capabilities of any papal university, made possible through partnership with UBS partners James Mallahan and Mark Russo.
Delos is the founder of the International WELL Building Institute (IWBI), which created the WELL Building Standard™, currently being implemented in over 4,000 projects, surpassing 500 million square feet of wellness real estate in 61 countries. IWBI recently established a Task Force on Covid-19 and other respiratory infections - Co-Chaired by 17th Surgeon General of the United States Richard Carmona, Former Robert Wood Johnson Foundation President and CEO Dr. Risa Lavizzo-Mourey, UCLA’s Dr. Jonathan Fielding, and Harvard School of Public Health’s Joseph Allen – to advance the role of buildings in protecting and enhancing health.
About Delos
Delos is a wellness real estate and technology company with a mission to be the world’s leading catalyst for improving the health and well-being of people by improving the indoor environments where they live, work, sleep and play. Informed by more than seven years of research and rigorous analysis of environmental health impacts on people, Delos and its subsidiaries offer an array of evidence-based technology and solutions for the built environment. Delos is the founder of the International WELL Building Institute and the WELL Building Standard, the premier standard for buildings, interior spaces and communities seeking to implement, validate and measure features that support and advance human health and wellness. The International WELL Building Institute administers and continues WELL’s development and drives market adoption. Delos collaborated with the Mayo Clinic to create the Well Living Lab, a scientific research center that uses exclusively human-centered research to understand the interaction between health and well-being and indoor environments. The company’s advisory board is comprised of leading professionals across real estate, healthcare, government policy and sustainability, including the 17th Surgeon General of the United States Richard Carmona, UCLA’s Dr. Jonathan Fielding, renowned wellness luminary Deepak Chopra, and sustainability advocate Leonardo DiCaprio. For more information about Delos, please visit www.delos.com
.
About Humanity 2.0 Well-Being
Humanity 2.0 was created to facilitate collaborative ventures between the historically siloed public, private, and faith-based sectors. Founded in 2018 in collaboration with the Dicastery for Integral Human Development at the Holy See (Vatican) led by His Eminence Cardinal Peter Turkson, the Humanity 2.0 Foundation has become a unique global force in its novel ability to identify important global initiatives, forge partnerships, and introduce scientific solutions for global impact. After two years of convenings in Vatican City with global luminaries from Ethics, Science, Health, and Technology, Humanity 2.0 Well Being was developed to focus more concretely on installing the world’s leading environmental and maternal wellness solutions throughout the Faith Sector and beyond. https://humanity2-0.org/
About the Pontifical Orientale Institute
The Mission of the Orientale is to pursue research, teaching, and publishing relating to the traditions of the Eastern Churches – a geography spanning from Russia to Ethiopia and from Italy to India - in their theology, liturgies, patristics, history, canon law, literature and languages, spirituality, archeology, and questions of ecumenical and geopolitical importance. The areas of primary concern today to the Orientale are the Middle East and the post-Soviet world. For more information about the Orientale, please visit https://orientale.it/en/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200511005558/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hisense Delivers 38% Sales Uplift in Western Europe Markets With NIQ’s AI-Powered Market Intelligence6.5.2026 05:00:00 CEST | Press release
NIQ insights drive international expansion and measurable growth for Hisense across key global markets NIQ (NYSE: NIQ), a global leader in consumer intelligence, today shared new learnings from its long-standing collaboration with Hisense, a leading global brand in home appliances and smart technologies. Using NIQ’s AI‑powered market intelligence, Hisense has accelerated international expansion, improved local market decision-making, and delivered measurable growth across more than 20 key markets and 12+ categories. The case study demonstrates how AI‑driven insights help global brands move faster, localize better, and compete more effectively in complex markets. The Challenge As Hisense expanded internationally, it faced rising complexity across global markets. Consumer preferences differed sharply across regions such as Western Europe, Eastern Europe, and Latin America, making a one‑size‑fits‑all approach ineffective. NIQ’s AI‑powered intelligence delivered the local market depth need
Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 01:00:00 CEST | Press release
Phase 1 study has demonstrated pharmacokinetics (PK) equivalence between SB27 and KeytrudaPhase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints. The randomized, double-blind, three-arm, parallel group, multicenter clinical trial demonstrated pharmacokinetic bioequivalence of SB27 (pembrolizumab) to the reference product Keytruda. Initiated in January 2024, Phase 1 study is being conducted in four countries, and is expected to be completed by November 2026.2 The study assessed pharmacokinetics, efficacy, safety, and immunogenicity of SB27, EU-sourced Keytruda, and US-sourced Keytruda in patients with stage II or IIIA non-small cell lung cancer (NSCLC) following complete resection and adjuvant platinum-based chemotherapy. 163 participants were randomized to receive SB27, EU-sourced Keytruda, or US-sour
Megaport Launches Built-In DDoS Protection Enabling On-Demand Network Resilience6.5.2026 00:00:00 CEST | Press release
Megaport DDoS Protection removes the trade-off between security, performance, and cost, offering rapid enterprise-grade mitigation. Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of Megaport DDoS Protection. This new, built-in security capability for Megaport Internet allows customers to filter malicious traffic directly within the Megaport network rather than routing it through a separate or external service, for mission-critical uptime without introducing additional latency or routing complexity. As enterprises increasingly migrate to distributed cloud environments, traditional DDoS mitigation has struggled to keep pace with cloud and distributed infrastructure adoption. Standard ISP solutions often resort to dropping all traffic and taking the service offline to protect the network, while external third-party providers force a "security detour" that reroutes traffic through public infrastructure, introducing s
IFF Reports First Quarter 2026 Results5.5.2026 22:23:00 CEST | Press release
Delivered solid top and bottom line Q1 resultsProgressing disciplined sale process for Food Ingredients businessReaffirms Full Year 2026 Financial Guidance IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Consolidated Summary: Management Commentary “IFF is off to a solid start in 2026, with first quarter results that reflect the customer focus and operational execution we’ve been building across the company,” said Erik Fyrwald, CEO of IFF. “We delivered volume growth in all four segments, improved profitability, and generated strong cash flow in the first quarter. As we look ahead, we are maintaining a disciplined approach to how we are planning the balance of the year as the current operating environment remains unsettled. We remained focused on advancing our commercial and innovation pipelines, driving productivity, and working with customers to offset inflation. This – when combined with our solid start to the year – derisks t
Logitech Announces Q4 and Full Fiscal Year 2026 Results5.5.2026 22:06:00 CEST | Press release
Strong FY 2026 Demonstrates Strategy and Operating Principles Are Delivering SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2026. For Fiscal Year 2026: Sales were $4.84 billion, up 6 percent in US dollars and 4 percent in constant currency compared to the prior year. GAAP operating income was $775 million, up 18 percent compared to the prior year. Non-GAAP operating income was $911 million, up 18 percent compared to the prior year. GAAP earnings per share was $4.80, up 16 percent compared to the prior year. Non-GAAP EPS was $5.78, up 19 percent compared to the prior year. Cash flow from operations was $1.04 billion. The year-ending cash balance was $1.7 billion. The Company returned $768 million of cash to shareholders through its annual dividend payment and share repurchases. For Q4 Fiscal Year 2026: Sales were $1.09 billion, up 7 percent in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
